We conducted survival analysis based on five subtypes; namely, luminal A, luminal BK (Ki67 ≥ 14%), luminal BH (HER2 overexpression), HER2 overexpression, and triple-negative breast cancer (Figures 1(c) and 1(d)). This evidence concerns the gene MKI67 and triple-negative breast carcinoma.